Characteristics | no DM | Treated DM ( | Untreated DM | P |
---|---|---|---|---|
Number | 2036 | 243 | 733 | |
Age (year) | 57.95 (11.26) | 61.43 (10) | 59.19 (11.54) | < 0.001 |
Male (N%) | 1551 (76.18%) | 179 (73.66%) | 509 (69.44%) | 0.002 |
Smoking (N %) | 381 (21.12%) | 44 (18.11%) | 131 (17.90%) | 0.137 |
Alcohol (N %) | 120 (6.66%) | 19 (7.82%) | 29 (3.96%) | 0.017 |
Family history (N %) | 178 (9.87%) | 26 (10.70%) | 54 (7.39%) | 0.109 |
BMI (kg/m2) | 22.43 (2.86) | 24.02 (3.4) | 23.35 (3.28) | < 0.001 |
Metformin (N %) | NA | 170 (69.96%) | NA | |
Sulfonylurea (N %) | NA | 54 (22.22%) | NA | |
Glucosidase inhibitor (N %) | NA | 4 (1.65%) | NA | |
Insulin (N %) | NA | 5 (2.06%) | NA | |
Unclear (N %) | NA | 22 (9.05%) | NA | |
SBP (mmHg) | 122.46 (18.65) | 126.49 (19.61) | 133.65 (21.77) | < 0.001 |
DBP (mmHg) | 76.51 (11.16) | 77.92 (11.47) | 78.42 (12.94) | 0.001 |
FPG (mmol/L) | 4.87 (0.74) | 8.49 (2.61) | 9.15 (2.67) | < 0.001 |
TG (mmol/L) | 1.09 (0.71) | 1.55 (1.27) | 1.37 (1.05) | < 0.001 |
TC (mmol/L) | 4.49 (1) | 4.59 (1.03) | 4.57 (1.24) | < 0.001 |
HDL (mmol/L) | 1.1 (0.35) | 0.92 (0.34) | 0.93 (0.47) | 0.011 |
LDL (mmol/L) | 2.95 (0.88) | 2.99 (0.92) | 3.04 (1.02) | 0.293 |
TNM stage (N%) | < 0.001 | |||
I | 280 (14.97%) | 30 (12.35%) | 34 (4.66%) | |
II | 314 (16.78%) | 38 (15.64%) | 72 (9.88%) | |
III | 1048 (56.01%) | 146 (60.08%) | 422 (57.89%) | |
IV | 229 (12.24%) | 29 (11.93%) | 201 (27.57%) | |
Pathological type (N%) | 0.252 | |||
Adenocarcinoma | 1426 (78.74%) | 181 (74.79%) | 540 (74.59%) | |
Signet-ring cell | 357 (19.71%) | 54 (22.31%) | 171 (23.62%) | |
Neuroendocrine | 14 (0.77%) | 4 (1.65%) | 7 (0.97%) | |
Other | 14 (0.77%) | 3 (1.24%) | 6 (0.83%) | |
Differentiated | < 0.001 | |||
High | 25 (1.38%) | 3 (1.24%) | 6 (0.83%) | |
Middle | 734 (40.55%) | 90 (37.19%) | 222 (30.66%) | |
Low | 1051 (58.07%) | 149 (61.57%) | 496 (68.51%) | |
Chemotherapy (N %) | 608 (29.8%) | 101 (32.4%) | 151 (30.4%) | 0.010 |
Chemotherapy courses (N) | 3.51 (2.4) | 4.09 (2.4) | 3.61 (2.3) | 0.078 |